MetLife Rises on 443rd-Tier Trading Volume as Analysts Split on Price Targets

MetLife (MET) rose 0.53% on August 18, 2025, with a trading volume of $0.21 billion, ranking 443rd in market activity. Recent analyst activity highlights mixed adjustments to price targets, reflecting evolving expectations for the insurer’s performance. Morgan Stanley reduced its target to $94 from $98, maintaining an "Overweight" rating. Keefe, Bruyette & Woods cut its target to $92 from $94, while Jefferies raised its target to $103 from $100. UBS also lowered its target to $91 from $94. These moves follow prior revisions in July, including a $98-to-$94 target cut by UBS and a $94-to-$97 increase by Wells Fargo. Analysts collectively project a 12-month average target of $93.58, suggesting potential upside from current levels.

MetLife operates across six segments, with Group Benefits and Retirement & Income Solutions accounting for 48% of 2024 adjusted earnings. The Asia segment, primarily Japan, contributes 25%, while Latin America adds 13%. Earnings stability is supported by consistent revenue growth over the past three years, though dividend yields have declined since 2020. The company’s balance sheet shows total assets of $677.46 billion as of 2024, with liabilities at $649.75 billion. EBIT of $6.75 billion in the trailing twelve months underscores operational resilience amid sector challenges.

Analysts’ average recommendation of 2.1 (on a 1–5 scale) indicates a "Outperform" outlook, aligning with the 21.54% upside implied by price targets. However, divergent views persist, as seen in the $82–$108 target range. The firm’s Sharpe ratio of 1.37 over five years suggests strong risk-adjusted returns compared to peers. Recent financial updates include a $4.29 billion net income for the trailing twelve months and $72.08 billion in total revenue, reflecting steady but modest growth.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a total profit of $10,720 as of the latest data.